ScoreWhy is Suven Pharmaceuticals Ltd ?
1
High Management Efficiency with a high ROE of 24.43%
2
Company has a low Debt to Equity ratio (avg) at 0 times
3
Poor long term growth as Operating profit has grown by an annual rate -5.48% of over the last 5 years
4
Positive results in Dec 24
- PBDIT(Q) Highest at Rs 117.70 cr.
- PBT LESS OI(Q) At Rs 94.02 cr has Grown at 47.3% (vs previous 4Q average)
- PAT(Q) Highest at Rs 82.88 cr.
5
Stock is technically in a Mildly Bullish range
- The stocks KST and OBV technical factors are also Bullish
6
With ROE of 12.3, it has a Very Expensive valuation with a 13.5 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 83.75%, its profits have fallen by -24.7%
7
High Institutional Holdings at 27.53%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
8
Market Beating performance in long term as well as near term
- Along with generating 83.75% returns in the last 1 year, the stock has outperformed BSE 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Suven Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Drugs should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Suven Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Suven Pharma
82.02%
2.28
36.71%
SENSEX
0.45%
0.03
14.48%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
3.10%
EBIT Growth (5y)
-5.48%
EBIT to Interest (avg)
57.78
Debt to EBITDA (avg)
0.23
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.71
Tax Ratio
23.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
27.53%
ROCE (avg)
36.25%
ROE (avg)
24.43%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
96
Industry P/E
33
Price to Book Value
13.54
EV to EBIT
85.22
EV to EBITDA
69.77
EV to Capital Employed
19.29
EV to Sales
24.95
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
19.38%
ROE (Latest)
12.29%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
PBDIT(Q)
Highest at Rs 117.70 cr.
PBT LESS OI(Q)
At Rs 94.02 cr has Grown at 47.3% (vs previous 4Q average
PAT(Q)
Highest at Rs 82.88 cr.
NET SALES(Q)
Highest at Rs 307.15 cr
EPS(Q)
Highest at Rs 3.26
-5What is not working for the Company
ROCE(HY)
Lowest at 16.19%
DEBTORS TURNOVER RATIO(HY)
Lowest at 5.23 times
CASH AND CASH EQUIVALENTS(HY)
Lowest at Rs 42.15 cr
Loading Valuation Snapshot...
Here's what is working for Suven Pharma
Operating Profit (PBDIT) - Quarterly
Highest at Rs 117.70 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 94.02 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 94.02 cr has Grown at 47.3% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 63.81 CrMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 82.88 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 307.15 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Net Sales - Quarterly
At Rs 307.15 cr has Grown at 27.8% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 240.29 CrMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 3.26
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Suven Pharma
Debtors Turnover Ratio- Half Yearly
Lowest at 5.23 times and Fallen
each half year in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 42.15 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
